Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients
- PMID: 8015728
- DOI: 10.1016/0304-3940(94)90746-3
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients
Abstract
Tumor necrosis factor-alpha (TNF-alpha), a glial-cell-related factor, was measured for the first time in the brain (striatum) and cerebrospinal fluid (CSF) from control and parkinsonian patients by a sensitive sandwich enzyme immunoassay. The concentrations of TNF-alpha in the brain and CSF were significantly higher in parkinsonian patients than those in controls. Since TNF-alpha is an important signal transducer of the immune system with cytotoxic and stimulator properties, these results suggest that an immune response may occur in the nigrostriatal dopaminergic regions in Parkinson's disease and that TNF-alpha may be related, at least in part, to the neuronal degeneration.
Similar articles
-
Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease.Neurosci Lett. 1995 Jun 30;193(2):129-32. doi: 10.1016/0304-3940(95)11686-q. Neurosci Lett. 1995. PMID: 7478158
-
Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease.Neurosci Lett. 1996 Jun 14;211(1):13-6. doi: 10.1016/0304-3940(96)12706-3. Neurosci Lett. 1996. PMID: 8809836 Clinical Trial.
-
Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease.J Neural Transm Park Dis Dement Sect. 1995;9(1):87-92. doi: 10.1007/BF02252965. J Neural Transm Park Dis Dement Sect. 1995. PMID: 7605592
-
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.Neurosci Lett. 1994 May 19;172(1-2):151-4. doi: 10.1016/0304-3940(94)90684-x. Neurosci Lett. 1994. PMID: 8084523
-
Cytokines in Parkinson's disease.J Neural Transm Suppl. 2000;(58):143-51. J Neural Transm Suppl. 2000. PMID: 11128604 Review.
Cited by
-
Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2.Cells. 2023 Dec 26;13(1):53. doi: 10.3390/cells13010053. Cells. 2023. PMID: 38201257 Free PMC article.
-
Free water imaging in Parkinson's disease and atypical parkinsonian disorders.J Neurol. 2024 May;271(5):2521-2528. doi: 10.1007/s00415-024-12184-9. Epub 2024 Jan 24. J Neurol. 2024. PMID: 38265472
-
Adjunctive therapy in Parkinson's disease: the role of rasagiline.Neuropsychiatr Dis Treat. 2012;8:285-94. doi: 10.2147/NDT.S25142. Epub 2012 Jul 2. Neuropsychiatr Dis Treat. 2012. PMID: 22802692 Free PMC article.
-
Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson's Disease.Biomolecules. 2024 Jan 5;14(1):73. doi: 10.3390/biom14010073. Biomolecules. 2024. PMID: 38254673 Free PMC article. Review.
-
Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.AAPS J. 2006 Sep 29;8(3):E606-21. doi: 10.1208/aapsj080369. AAPS J. 2006. PMID: 17025278 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical